Home Cart Sign in  
Chemical Structure| 1898283-02-7 Chemical Structure| 1898283-02-7

Structure of LY3200882
CAS No.: 1898283-02-7

Chemical Structure| 1898283-02-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LY3200882 is a novel and highly selective inhibitor of TGF-β receptor type 1 (TGFβRI).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LY3200882

CAS No. :1898283-02-7
Formula : C24H29N5O3
M.W : 435.52
SMILES Code : OC(C)(C)C1=NC=CC(NC2=NC=CC(OC3=CN(C4CC4)N=C3C5CCOCC5)=C2)=C1
MDL No. :MFCD31619238
InChI Key :PNPFMWIDAKQFPY-UHFFFAOYSA-N
Pubchem ID :121249291

Safety of LY3200882

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Orthotopic models of head and neck and lung cancer Oral gavage 75 mg/kg, twice daily Twice daily for 2 weeks To evaluate the efficacy of LY3200882 in combination with radiotherapy, results showed TGFβ pathway inhibition enhanced the efficacy of RT. PMC8932273
Mice Colorectal cancer models (MC38 and CT26) Oral gavage 105–150 mg/kg Twice daily, 12 hours apart, for 7 days Evaluate the antitumor efficacy of LY3200882 in combination with chemotherapy and radiation, showing significant survival extension and enhanced CD8+T cell infiltration PMC7145847

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04031872 Colorectal Cancer Metastatic PHASE1|PHASE2 UNKNOWN 2025-07-21 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.30mL

0.46mL

0.23mL

11.48mL

2.30mL

1.15mL

22.96mL

4.59mL

2.30mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories